SUNNYVALE, California, May 11, 2011 /PRNewswire/ -- Accuray Incorporated , a global leader in the field of radiosurgery, announced today that 85 percent of European CyberKnife(R) centers are performing prostate SBRT to treat localized prostate cancer. There is an increasing trend towards treating prostate cancer patients with a hypofractionated regimen.

"More than 25 percent of our CyberKnife patients are being treated for prostate cancer with further growth anticipated," said Dr David Feltl, Head of the Oncology department, Ostrava University Hospital, Ostrava, Czech Republic.

SAN DIEGO, May 11, 2011 /PRNewswire/ -- Amira Pharmaceuticals, Inc. announced today that it will present preclinical data on AM152, an LPA1 receptor antagonist, during the Annual Meeting of the American Thoracic Society (ATS) in Denver, Colorado. The poster, titled "The LPA1 Antagonist, AM152, Is Efficacious in Mouse Models of Fibrosis," will be presented on Monday, May 16, from 8:15 to 10:45 a.m. MDT.

Driver safety technology is a key factor in preventing accidents and creating a crash-free future for drivers, says Andy Yeoman, managing director of Trimble Mobile Resource Management (MRM) in Europe, a provider of telematics technology. 

 Studies have shown the majority of road traffic accidents are a result of driver behavior or distractions but a recent study from UK road safety charity Brake suggests that the majority of drivers believe they are safer than, or as safe as, the average driver and are quick to place blame on third parties instead.

 
Approximately 55  million people in Europe are living with diabetes and many require insulin to manage their condition. For people who use insulin, managing diabetes can often involve challenging calculations to determine an appropriate mealtime insulin dose. Individuals soemtimes have trouble with the calculations required for insulin dose adjustment, resulting in insulin dose calculation errors.